Signature of a collaboration and licensing agreement with Boehringer Ingelheim to develop an innovative treatment called K1K1 for patients with pulmonary fibrosis.
Congratulations to Oleg Melnyk, Jérôme Vicogne and their colleagues at CIIL who generated the initial data demonstrating the therapeutic potential of K1 domain multimerization and characterized K1K1 activity in vitro and in vivo.
SATT Nord-led Academic Partnership Collaborates with Boehringer Ingelheim to Develop a Novel Treatment for People Living with Pulmonary Fibrosis
SATT Nord (Technology transfer office) and its partners from Centre National de la Recherche Scientifique (CNRS), University of Lille, Pasteur Institute of Lille, University of Paris-Cité, France and University of Pavia, Italy are entering in collaboration and licensing agreements with Boehringer Ingelheim with the goal to advance an innovative treatment called K1K1 into clinical development for the treatment of people living with pulmonary fibrosis.
